Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.59 |
| ▸ | ELOC | Q15369 | 5/20 | 0.49 |
| ▸ | ELOB | Q15370 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413085 | 0.92 | VHL (0.61) | VHLELOCELOB | |
| SCHEMBL25411363 | 0.92 | VHL (0.61) | VHLELOCELOB | |
| SCHEMBL25411369 | 0.92 | VHL (0.61) | VHLELOCELOB | |
| SCHEMBL25413091 | 0.92 | VHL (0.61) | VHLELOCELOB | |
| SCHEMBL31398422 | 0.89 | VHL (0.67) | VHLELOCELOB | |
| SCHEMBL30843443 | 0.89 | VHL (0.67) | VHLELOCELOB | |
| SCHEMBL30753891 | 0.86 | VHL (0.62) | VHLELOCELOB | |
| SCHEMBL29448118 | 0.86 | VHL (0.64) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL25271423 | 0.85 | VHL (0.63) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL25222920 | 0.85 | VHL (0.63) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-02-19 | — | — | US | disclosed |
| EP-4567033-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| CN-119630656-A | Heterocyclic compounds for inducing cleavage of mutant KRAS proteins | 安斯泰来制药株式会社 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024261256-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | VHL 26/4885ELOC 1814/4885ELOB 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.